First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007

P. Fields; W. M. Townsend; A. Webb; C. F. E. Pocock; P. Smith; A. Kirkwood; N. El-Mehidi; P. W. Johnson; J. Radford; D. C. Linch; D. Cunningham

First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007

P. Fields, W. M. Townsend, A. Webb, C. F. E. Pocock, P. Smith, A. Kirkwood, N. El-Mehidi, P. W. Johnson, J. Radford, D. C. Linch, D. Cunningham

Research output: Contribution to journal › Article › peer-review

Original language	Undefined
Journal	British Journal of Haematology
Volume	157
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Fields, P., Townsend, W. M., Webb, A., Pocock, C. F. E., Smith, P., Kirkwood, A., El-Mehidi, N., Johnson, P. W., Radford, J., Linch, D. C., & Cunningham, D. (2012). First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. British Journal of Haematology, 157.

Fields, P. ; Townsend, W. M. ; Webb, A. et al. / First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. In: British Journal of Haematology. 2012 ; Vol. 157.

@article{6d09f15a8fbc444ab5b7846563192c96,

title = "First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007",

author = "P. Fields and Townsend, {W. M.} and A. Webb and Pocock, {C. F. E.} and P. Smith and A. Kirkwood and N. El-Mehidi and Johnson, {P. W.} and J. Radford and Linch, {D. C.} and D. Cunningham",

year = "2012",

language = "Undefined",

volume = "157",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley & Sons Ltd",

}

Fields, P, Townsend, WM, Webb, A, Pocock, CFE, Smith, P, Kirkwood, A, El-Mehidi, N, Johnson, PW, Radford, J, Linch, DC & Cunningham, D 2012, 'First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007', British Journal of Haematology, vol. 157.

First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. / Fields, P.; Townsend, W. M.; Webb, A. et al.
In: British Journal of Haematology, Vol. 157, 2012.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007

AU - Fields, P.

AU - Townsend, W. M.

AU - Webb, A.

AU - Pocock, C. F. E.

AU - Smith, P.

AU - Kirkwood, A.

AU - El-Mehidi, N.

AU - Johnson, P. W.

AU - Radford, J.

AU - Linch, D. C.

AU - Cunningham, D.

PY - 2012

Y1 - 2012

UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000302795700031&KeyUID=WOS:000302795700031

M3 - Article

SN - 0007-1048

VL - 157

JO - British Journal of Haematology

JF - British Journal of Haematology

ER -

Fields P, Townsend WM, Webb A, Pocock CFE, Smith P, Kirkwood A et al. First analysis of a phase II multicentre trial of rituximab, gemcitabine, cyclophosphamide, vincristine and prednisolone (R-GCVP) for patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) considered unsuitable for anthracycline containing chemo-immunotherapy. An NCRI lymphoma clinical studies group trial. CRUK/07/007. British Journal of Haematology. 2012;157.

UN SDGs

Other files and links

Cite this